Another recent meta-analysis, which included 34 studies and 6261 patients with T2DM, in humans confirmed that the administration of SGLT-2 inhibitors was associated with improvements in inflammatory biomarkers as well. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.